Tailoring Patient Care Using Novel Agents in Metastatic Urothelial Carcinoma: Strategies for the Interprofessional Team

The treatment paradigm in bladder cancer has fundamentally changed over the past decade, and the evolving, dense clinical trial landscape has given rise to barriers to optimizing patient care. This Community Connections Grand Rounds series will focus on emerging trial data for antibody-drug conjugates (ADCs); sequence optimization, combinatorial therapy utilization, and identification of when and in which patients to use ADCs; and anticipation, recognition, and management of treatment-related adverse events (TRAEs) in patients with metastatic urothelial cancer (mUC).

Join our expert faculty for this 60-minute activity designed to help clinicians stay abreast of emerging trial data and evolving treatment guidelines, as well as effectively manage agent-specific AEs, to optimize care for their patients with mUC.

At the conclusion of this activity, learners will be able to better:

• Assess the evidentiary base for ADCs in metastatic disease, including regulatory updates, recent readouts, and current expert consensus guideline recommendations
• Utilize evidence from pivotal clinical trials in mUC to develop personalized ADC-based treatment regimens based on patient- and disease-specific characteristics
• Implement an interprofessional approach to AE anticipation, recognition, and management for patients with mUC treated with ADC-based regimens

This program has been supported by an independent educational grant from Gilead Sciences, Inc.

Community oncologists, urologists, physician associates (PAs), oncology nurse practitioners (NPs), nurses, and pharmacists

Faculty

Dr. Dreicer, reports the following financial relationships:

Advisory Board: Astellas Pharma Inc.; Bayer; Gilead Sciences, Inc.; MacroGenics, Inc.; and Pfizer Inc.

Consultant: Merck & Co., Inc.

Research Support: Arvinas and Exelixis, Inc.

Planners

Dr. Petros Grivas, MD, PhD, reports the following financial relationships:

Consulting/Advisory Role: Aadi Bioscience; Abbvie Inc.; Asieris Pharmaceuticals; Astellas Pharma Inc.; AstraZeneca; Bristol Myers Squibb Company; Bicycle Therapeutics; CG Oncology; EMD Serono; Fresenius Kabi; G1 Therapeutics, Inc.; Gilead Sciences, Inc.; ImmunityBio, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Pfizer Inc.; Roche; and Strata Oncology, Inc.

Research Funding: (paid to institution): Acrivon Therapeutics; ALX Oncology Inc.; Bristol Myers Squibb Company; EMD Serono; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Merck & Co., Inc.; Mirati Therapeutics, Inc.; and QED Therapeutics

Dr. Daniel P. Petrylak, MD, reports the following financial relationships:

Consultant:  Advanced Accelerator Applications; Amgen Inc.; Astellas Pharma Inc.; AstraZeneca; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Bristol Myers Squibb Company; Clovis Oncology; Lilly; Exelixis, Inc.; Gilead Sciences, Inc.; Incyte; Infinity Pharmaceuticals, Inc.; Ipsen Pharma; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Monopteros Therapeutics, Inc.; Pfizer Inc.; Pharmacyclics; Regeneron Pharmaceuticals Inc.; Roche; Sanofi; Seattle Genetics, Inc.; and UroGen Pharma, Inc.

Grant/Research Support:  Adlai Nortye Ltd.; Advanced Accelerator Applications; Agensys, Inc.; Arvinas; Astellas Pharma Inc.; AstraZeneca; Bayer; BioXcel Therapeutics, Inc.; Bristol Myers Squibb Company; Clovis Oncology; Daiichi Sankyo Company, Limited; Eisai; Lilly; Endocyte, Inc.; Ferring Pharmaceuticals; Genentech, Inc.; Gilead Sciences, Inc.; Innocrin Pharmaceuticals Inc.; MacroGenics, Inc.; MedImmune; Medivation, Inc.; Merck & Co., Inc.; Mirati Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Progenics Pharmaceuticals, Inc.; Replimune Group Inc.; Roche; Sanofi, and Seattle Genetics, Inc.

Ms. Terran W. Sims MSN, ACNP-C, CNN, COCN-C,  reports the following financial relationships:

Consultant: Coloplast US Ostomy

The following individuals have no financial relationships to disclose: 

Rebecca Vargas-Jackson, MD  (Peer Reviewer)
Elizabeth Naber, MSN, RN, CCRN-K, CNRN, TCRN (Peer Reviewer)
David Modrak, PhD (Planning Committee)
Katherine E. Lee, PharmD, MPH (Planning Committee)
Nichole Lainhart (Planning Committee)
Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)